| Prev Close | 168.01 |
| Day Low/High | 167.00 / 171.22 |
| 52 Wk Low/High | 110.52 / 169.67 |
| Avg Volume | 1.61M |
McKesson Corp. (MCK)
170.78
NYSE : Distribution Services
| Exchange | NYSE |
| Shares Outstanding | 177.08M |
| Market Cap | 29.75B |
| EPS | 0.20 |
| P/E Ratio | N/A |
| Div & Yield | 1.64 (0.95%) |
Latest News
Sussing the Fed -- Plus Apple, Amgen and Other Earnings: Market Recon
Markets are watching what Fed Chair Powell will signal for future rate cuts during this afternoon's FOMC rate decision.
McKesson Is Poised to Make a Significant Upside Breakout
Traders need to respect this price strength.
Jim Cramer: Here's Why the Market's So Feckless and Reactive
So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.
Fed Front and Center, Apple Earnings, Trading AMD: Market Recon
Understand that the expected Fed rate cut today is not about recent economic performance in the least.
Here Are 20 Companies to Watch for Dividend Increases This Week
We have more than 1,050 companies reporting quarterly earnings from Monday to Friday, and here are the ones to keep focus on.
Jim Cramer: What to Buy and What to Avoid on Trump's Latest China Tweet
As usual, the stocks that bounce back first are the tech stocks with little Chinese exposure and the consumer packaged goods that just demonstrated good numbers.
3 Top Healthcare Stocks Ripe For the Buying
I've spotlighted three blue-chip companies with stock prices that are at ridiculously low valuations right now.
McKesson or Cardinal Health: Which Is a Better Dividend Yield Buy?
Cardinal Health and McKesson have similar business models, but they are very different stocks.
Good Things Come to Those Who Wait
Undervalued shares can get even cheaper in the short run but eventually they play catch up, running much higher.
The Human Response Factor, Fed Moves, China Talks, MSFT Results: Market Recon
Many see the Fed as done for the year. Never assume. Read the words as they are written.
McKesson Hasn't Provided This Good a Value in a Decade
McKesson is a high-quality name with a very depressed valuation.
Time to Minimize Your Tax Bill With Tax-Loss Selling
Underwater positions on stocks you feel lukewarm about are prime candidates for tax selling.
Here Are 9 Takeaways From Last Night's Meltdown: Market Recon
It becomes difficult for me to tell you where to run in these markets...
Jim Cramer: Valuations Now Have No Relation to Common Sense
Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.
'Death by Amazon' Greatly Exaggerated
Contrarians who bought several "dead men walking" retailers have pocketed big gains by defying conventional wisdom.
CAH Is Among the Best Blue Chip Values
Buy Cardinal Health and give it time for the market to reassess the industry.
3 Best Chip Stocks to Own After AMD's Monster Earnings Beat: Market Recon
Micron Technology, Intel and Lam Research are good buys on this heat in semiconductors.
Easing Dodd-Frank Regulations on Smaller Banks Was Long Overdue: How to Play It
Relief is on the way, and there's an inexpensive beneficiary out in California.
Jim Cramer: It's All About Expectations
Earnings season is already seeing some wacky effects.
Who Says There Are No Second Chances?
A follow-up on my stock pick of the year, McKesson.
The Really Big Money Rushes to Super Bowl
This will be the ninth consecutive year when the big game tops that 100 million-viewers mark.
Jim Cramer: The 3 Best Sectors That Lifted the Stock Market
It's hard to understand the magnitude of the change.
Jim Cramer: I Blame the Pajama Traders for This Selloff
They make more irrational, stupid moves based on nothing than I ever thought possible.
Cramer: 5 Rules for Our Beast of a Bull Market
It might look easy now, but it looked easy in 1999, too.
A Controversial Pick of the Year for 2018
Nothing breeds future investment success like buying in the face of negative headlines.
My Controversial Pick of the Year for 2018
Nothing breeds future investment success like buying in the face of negative headlines.
The 5 Best 'Dividend Aristocrats' for 2018
The best high-yielding blue chips at discounted prices.
Will McKesson's Opioid Issue Linger?
Market is pricing the stock as if the side effects of this report will just go away.
